Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term marker. Found 18 abstracts

Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Mu ZM, Li H, Fernandez SV, Alpaugh KR, Zhang RG, Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. Journal of Experimental & Clinical Cancer Research. 2013 Sep;32:70.   PMCID: PMC 3850122
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Journal of surgical oncology. 2012 Jul;106(1):24-30.   PMCID: PMC3370134
Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec;117(24):5476-84.   PMCID: not NIH funded
Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, Saltarelli R, Chiapparino E, Spremberg F, Cristofanilli M, Frati L, Agliano AM, Gazzaniga P. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Annals of Oncology. 2011 Jan;22(1):86-92.   PMCID: not NIH funded
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult Tumor Burden Predicts Disease Recurrence in Lymph Node-Negative Colorectal Cancer. Clinical Cancer Research. 2011 May;17(10):3293-303.   PMCID: PMC3096730
Shoreibah MG, Jackson CL, Price PW, Meagher R, Godwin AK, Cai Q, Gildersleeve JC. Anti-Human Embryonic Stem Cell Monoclonal Antibody Hesca-2 Binds to a Glycan Epitope Commonly Found on Carcinomas. Stem Cells and Development. 2011 Mar;20(3):515-25.   PMCID: PMC3128762
Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers. Clinical Cancer Research. 2010 Dec;16(24):6132-8.   PMCID: PMC3057907
Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Plasma Cell-Free DNA in Ovarian Cancer An Independent Prognostic Biomarker. Cancer. 2010 Apr;116(8):1918-25.   PMCID: PMC2854845
Psyrri A, Yu ZW, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clinical Cancer Research. 2005 Aug 15;11(16):5856-62.
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. Journal of Clinical Oncology. 1999 Nov;17(11):3461-7.
Siegfried JM, Gillespie AT, Mera R, Casey TJ, Keohavong P, Testa JR, Hunt JD. Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiology Biomarkers & Prevention. 1997 Oct;6(10):841-7.
Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: The need for improved systemic and locoregional treatment. Journal of Clinical Oncology. 1996 Apr;14(4):1093-7.
Szarka CE, Pfeiffer GR, Hum ST, Everley LC, Balshem AM, Moore DF, Litwin S, Goosenberg EB, Frucht H, Engstrom PF, Clapper ML. Glutathione-S-Transferase Activity and Glutathione-S- Transferase Mu-Expression in Subjects with Risk for Colorectal- Cancer. Cancer Research. 1995 Jul;55(13):2789-93.
Damico AV, Hanks GE. Linear Regressive Analysis Using Prostate-Specific Antigen Doubling Time for Predicting Tumor Biology and Clinical Outcome in Prostate-Cancer. Cancer. 1993 Nov;72(9):2638-43.
Groshar D, McEwan AJ, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, Mercer JR, Mannan RH, Wiebe LI, Chapman JD. Imaging Tumor Hypoxia and Tumor Perfusion. Journal of Nuclear Medicine. 1993 Jun;34(6):885-8.
Ranganathan S, Tew KD. Analysis of Glyoxalase-I from Normal and Tumor-Tissue from Human Colon. Biochimica et biophysica acta. 1993 Oct 20;1182(3):311-6.
Mannan RH, Mercer JR, Wiebe LI, Somayaji VV, Chapman JD. Radioiodinated 1-(2-Fluoro-4-Iodo-2,4-Dideoxy-Beta-L- Xylopyranosyl)-2-Nitroimidazole - a Novel Probe for the Noninvasive Assessment of Tumor Hypoxia. Radiation Research. 1992 Dec;132(3):368-74.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term marker

marker carcinoma expression cancer progression survival therapy breast-cancer disease epithelial-cells adenocarcinoma diagnosis serum radiation-therapy proliferation lung-cancer quantification guanylyl cyclase-c colon-cancer micrometastases time adjuvant chemotherapy cetuximab glutathione-s-transferase treated patients receptor gene-expression disparities confidence-intervals pancreatic-cancer colon tissue growth Cancer stem cell prognosis spectroscopy colon enhancer colorectal-cancer enzyme (human) lacto-n-hexaose solid tumors profile Inflammatory breast cancer peritoneal mesothelioma ss1p human epidermal growth factor receptor 2 susceptibility metabolism messenger-rna ovarian-cancer agent histone methyltransferase ezh2 doubling time recombinant drug ras gene-mutations estrogen-receptor serum dna EZH2 human-milk estrogen prostate cancer identification prostate-cancer phase-ii trial system colorectal carcinoma invitro differentiation benign carcinomas cell lung-cancer tumor subtypes formation inflammatory breast cancer glyoxalase-i breast cancer chemotherapy resistance reduction zeste homolog-2 predictive-value barr-virus dna p53 patient tumors localization radical prostatectomy tissue microarrays Tumor spheroid real-time polymerase chain reaction cell-free DNA-prognosis-ovarian cancer-biomarker adenocarcinomas galectin-1 nasopharyngeal carcinoma recurrence invivo enhancer of zeste homolog 2 immunotoxin proteins bone-marrow circulating tumor cells circulating dna tumor marker stem-cells leukocytes oligosaccharides tumor inhibition bladder serum antibodies stage neck colorectal cancer lymph node collection-molecular staging-occult tumor burden-guanylyl cyclase C misonidazole cancer stem cells head outcome prediction glutathione s-transferases polyacrylamide gels quantitation tumor doubling cell-lines recommendations thymidine kinase 1 infusion irradiation biology dna-repair embryonic stem-cells cells microarrays prostate-specific antigen
Last updated on Wednesday, February 05, 2020